These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 30187275)

  • 1. Development of scoliosis in young children with osteogenesis imperfecta undergoing intravenous bisphosphonate therapy.
    Kashii M; Kanayama S; Kitaoka T; Makino T; Kaito T; Iwasaki M; Kubota T; Yamamoto T; Ozono K; Yoshikawa H
    J Bone Miner Metab; 2019 May; 37(3):545-553. PubMed ID: 30187275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment.
    Sato A; Ouellet J; Muneta T; Glorieux FH; Rauch F
    Bone; 2016 May; 86():53-7. PubMed ID: 26927310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up in osteogenesis imperfecta type VI.
    Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
    Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
    Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of scoliotic curvature with Z-score bone mineral density and body mass index in patients with osteogenesis imperfecta.
    Watanabe G; Kawaguchi S; Matsuyama T; Yamashita T
    Spine (Phila Pa 1976); 2007 Aug; 32(17):E488-94. PubMed ID: 17762282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
    Falk MJ; Heeger S; Lynch KA; DeCaro KR; Bohach D; Gibson KS; Warman ML
    Pediatrics; 2003 Mar; 111(3):573-8. PubMed ID: 12612238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta.
    Apolinário AC; Figueiredo PT; Guimarães AT; Acevedo AC; Castro LC; Paula AP; Paula LM; Melo NS; Leite AF
    J Dent Res; 2015 Mar; 94(3 Suppl):95S-102S. PubMed ID: 25608973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.
    Zeitlin L; Rauch F; Plotkin H; Glorieux FH
    Pediatrics; 2003 May; 111(5 Pt 1):1030-6. PubMed ID: 12728084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dental panoramic indices and fractal dimension measurements in osteogenesis imperfecta children under pamidronate treatment.
    Apolinário AC; Sindeaux R; de Souza Figueiredo PT; Guimarães AT; Acevedo AC; Castro LC; de Paula AP; de Paula LM; de Melo NS; Leite AF
    Dentomaxillofac Radiol; 2016; 45(4):20150400. PubMed ID: 26954289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
    Feehan AG; Zacharin MR; Lim AS; Simm PJ
    Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavior of scoliosis during growth in children with osteogenesis imperfecta.
    Anissipour AK; Hammerberg KW; Caudill A; Kostiuk T; Tarima S; Zhao HS; Krzak JJ; Smith PA
    J Bone Joint Surg Am; 2014 Feb; 96(3):237-43. PubMed ID: 24500586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age.
    Kusumi K; Ayoob R; Bowden SA; Ingraham S; Mahan JD
    J Bone Miner Metab; 2015 Sep; 33(5):560-8. PubMed ID: 25319557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.
    Land C; Rauch F; Munns CF; Sahebjam S; Glorieux FH
    Bone; 2006 Oct; 39(4):901-6. PubMed ID: 16730480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
    Sousa T; Bompadre V; White KK
    J Pediatr Orthop; 2014 Jan; 34(1):118-22. PubMed ID: 23863411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment.
    Harada D; Kashiwagi H; Ueyama K; Oriyama K; Hanioka Y; Sakamoto N; Kondo K; Kishimoto K; Izui M; Nagamatsu Y; Yamada H; Tanaka H; Namba N; Seino Y
    J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1391-1397. PubMed ID: 33031051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy.
    Arikoski P; Silverwood B; Tillmann V; Bishop NJ
    Bone; 2004 Mar; 34(3):539-46. PubMed ID: 15003801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.